Search research articles
Contact Us
Filters
Showing results (181-190 of 218) with videos related to
Page
of 22
Sort By:
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
Future Oncology (London, England)
|
November 1, 2018
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
Markus Moehler, Min-Hee Ryu, Mikhail Dvorkin, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
JAMA Network Open
|
October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
Benoist Chibaudel, Julie Henriques, Manel Rakez, et al.
NPJ Genomic Medicine
|
May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients
Tom Venken, Ian S Miller, Ingrid Arijs, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Viruses
|
August 28, 2021
Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Dirk M Nettelbeck, Mathias F Leber, Jennifer Altomonte, et al.
The Lancet. Oncology
|
August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Future Oncology (London, England)
|
March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 218) with videos related to
Sort By:
Page
of 22
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
Future Oncology (London, England)
|
November 1, 2018
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
Markus Moehler, Min-Hee Ryu, Mikhail Dvorkin, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
JAMA Network Open
|
October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
Benoist Chibaudel, Julie Henriques, Manel Rakez, et al.
NPJ Genomic Medicine
|
May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients
Tom Venken, Ian S Miller, Ingrid Arijs, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Viruses
|
August 28, 2021
Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Dirk M Nettelbeck, Mathias F Leber, Jennifer Altomonte, et al.
The Lancet. Oncology
|
August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Future Oncology (London, England)
|
March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Page
of 22